Division of Johnson & Johnson
Latest From RespiVert Ltd.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2017.
Recently approved Bavencio will be paired with experimental MNK1/2 inhibitor in microsatellite-stable colorectal cancer. CRO Parexel to go private, AbbVie teams with Principia in immunology R&D and more.
With strong backing, F-Prime Capital Partners can make large, high-risk bets around the world — and keep doubling down. An interview with F-Prime Managing Partner Stephen Knight.
With the combination asthma inhaler Flutiform being rolled out across Europe by licensee Mundipharma, the U.K.'s SkyePharma aims now to concentrate on drug delivery research, not clinical development.
- Drug Delivery
- Therapeutic Areas
- Respiratory, Pulmonary
- Western Europe
- Parent & Subsidiaries
- Johnson & Johnson
- Senior Management
Garth Rapeport, MD, CEO
Peter Strong, PhD, Head, Drug Discovery
- Contact Info
Phone: (44) 79 0049 1827
50-100 Holmers Farm Way
High Wycombe, HP12 4EG
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.